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Abstract
Background: MicroRNAs (miRNAs) are short non-coding RNAs predicted to regulate one third of protein coding genes via
mRNA targeting. In conjunction with key transcription factors, such as the repressor REST (RE1 silencing transcription factor),
miRNAs play crucial roles in neurogenesis, which requires a highly orchestrated program of gene expression to ensure the
appropriate development and function of diverse neural cell types. Whilst previous studies have highlighted select groups
of miRNAs during neural development, there remains a need for amenable models in which miRNA expression and function
can be analyzed over the duration of neurogenesis.
Principal Findings: We performed large-scale expression profiling of miRNAs in human NTera2/D1 (NT2) cells during
retinoic acid (RA)-induced transition from progenitors to fully differentiated neural phenotypes. Our results revealed
dynamic changes of miRNA patterns, resulting in distinct miRNA subsets that could be linked to specific
neurodevelopmental stages. Moreover, the cell-type specific miRNA subsets were very similar in NT2-derived differentiated
cells and human primary neurons and astrocytes. Further analysis identified miRNAs as putative regulators of REST, as well
as candidate miRNAs targeted by REST. Finally, we confirmed the existence of two predicted miRNAs; pred-MIR191 and
pred-MIR222 associated with SLAIN1 and FOXP2, respectively, and provided some evidence of their potential co-regulation.
Conclusions: In the present study, we demonstrate that regulation of miRNAs occurs in precise patterns indicative of their
roles in cell fate commitment, progenitor expansion and differentiation into neurons and glia. Furthermore, the similarity
between our NT2 system and primary human cells suggests their roles in molecular pathways critical for human in vivo
neurogenesis.
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Introduction
miRNAs are small noncoding RNAs, identified through seminal
work in C. elegans [1–3], D. melanogaster and humans [4] and are
required for regulation of gene expression at the post-transcrip-
tional level. To date, the miRBase release 14.0 miRNA registry
(http://www.mirbase.org/) [5,6] lists over 10,000 miRNAs,
including 721 human miRNAs cloned and/or identified by
homology to other organisms. It is further estimated that their
total number in the human genome may exceed a thousand and
they may target approximately one-third of all human messenger
RNAs (mRNAs) [7].
Mature miRNAs of 18–22 nt in length are cleaved by the
ribonuclease III family member Dicer from 60–90 nt hairpin-loop
precursors (pre-miRNAs), and act to repress translation by binding
with partial sequence complementarity to the 39-UTRs of their
target mRNAs. Depending in part on the characteristics of the
mRNA promoter, miRNA:mRNA binding results in inhibition of
translation initiation or post-initiation translational block [8]. Each
miRNA is predicted to recognize multiple target mRNAs [9],
hence a single miRNA can have far-reaching effects on gene
expression and may modulate the expression of gene sets that
function together to control biological processes. This potential for
coordinated control of gene expression, coupled with wide-ranging
expression across multiple cell types and throughout development,
implies that miRNAs regulate such cellular processes as stem cell
self-renewal, fate determination and differentiation that are critical
for normal development.
Several studies examine the expression of miRNAs during
neurodevelopment as well as in the adult CNS and reveal that
certain miRNAs are found preferentially expressed in neurons, e.g.,
miR-124 and miR-128 [10], whereas others, e.g., miR-23, miR-26
and miR-29, seem restricted to astrocytes [11]. Accordingly miRNAs
have been implicated in many aspects of central nervous system
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development and function. For example, a recent report identifies
miR-124 as a regulator of adult neurogenesis via the regulation of
Sox9 in the subventricular zone stem cell niche [12]; whereas others
highlight a role of miRNAs in brain morphogenesis [13], and
neuronal cell specification [11,14–16]. There are also reports linking
non-coding RNAs with neurological disorders such as Parkinson’s
disease (miR-133b) [17], Huntington’s disease (miR-132, miR-9)
[18,19], Alzheimer’s disease (miR-29 and miR-107) [20,21], and
Tourette’s syndrome (miR-189) [22].
The majority of existing studies examine a select number of
miRNAs in the CNS and use PCR-based and/or Northern
blotting techniques [10,23–25]. A limited number of reports also
present analysis of miRNA expression during neural differentia-
tion of immortalized cell lines [26–28]. Sempere et al. [26]
describe the expression of 66 miRNAs in human NTera2 and
mouse P19 cells following retinoic acid (RA) treatment and
establish that 19 of them are coordinately up-regulated in both cell
lines indicating that their functions might be conserved between
the species. In another study, Hohjoh and Fukushima [27]
examine the profiles of 180 mouse and 127 human miRNAs in
human (NTera2/D1) and rodent (P19D and Neuro2a) cell lines,
and report that the ES cell specific miR-302 cluster [29,30] and
miR-124a [10] show the opposite patterns of expression in
response to the RA treatment and may mark the onset of neural
differentiation. In all tissues where it has been examined, it is
apparent that miRNAs are subject to dynamic regulation during
the process of development; however, to date, studies detailing
miRNA expression in brain report small subsets of miRNAs and/
or focus on specific tissues or sub-regions at restricted develop-
mental time-points. As such these studies, although valuable,
provide only a limited knowledge of the role of miRNAs in the
process of neurogenesis as they are unable to capture the full
dynamic profile of miRNA expression during neurogenesis and
thus do not successfully recapitulate the developmental regulation
of miRNAs in vivo. In particular, there are few studies that either
extensively address miRNA expression throughout the complete
duration of neurogenesis; or that define cell type-specific
expression, such as the differences between fully differentiated
neurons and glia.
To this end we undertook a large-scale microarray screening of
miRNA expression during the process of neural differentiation in
order to define expression patterns of miRNAs that can be linked
to different stages of neurodevelopment and, subsequently, to
specific pathways regulating neurogenesis. We used a human
embryonal carcinoma (EC) cell line, NTera2/D1 (NT2), which is
described as ‘‘a surrogate’’ of pluripotent embryonic stem cells that
can undergo a multistep transition from the undifferentiated state
to terminal neuronal differentiation. NT2, like pluripotent
embryonic stem cells, have the capacity to differentiate into
numerous cell types [31]. However when cultured at high-density
under a 28 day treatment with RA they follow a highly
reproducible neural differentiation program. RA-induced differ-
entiation of NT2 cells proceeds through distinct phases of neural
commitment, precursor expansion and terminal differentiation to
neurons and astroglia [32] and analysis of neural gene markers
shows a characteristic temporal and spatial pattern of gene
expression similar to neuroepithelial precursors during in vivo
neurogenesis [33,34]. We performed extensive time-course
analysis of 405 unique miRNAs during a four week RA-treatment
of NT2 cells as well as in NT2-derived astrocytes (NT2-A) and
NT2-derived post-mitotic neurons (NT2-N). Subsequently, we
compared the data generated on NT2-derived cells with that of
primary human neurons and astroglia. The large number of
miRNAs analyzed, plus the duration and completeness of the time
points examined significantly extend beyond those studies
published previously. This is, to our knowledge, the first study of
miRNA expression profiling extensively encompassing the dura-
tion of neurogenesis from surrogate human stem cells, through to
neural precursors and in particular highlights the differences in
miRNA expression of the terminally differentiated cell types (i.e.,
astroglia and post-mitotic neurons) originating from a common
pool of progenitors. This is also the first comprehensive
comparison of miRNA expression in NT2 neurons and astrocytes
to their primary human counterparts. We report here the dynamic
changes in miRNA expression during neural differentiation and
the identification of distinct subsets of miRNAs in NT2 neurons
and astrocytes, a pattern that is conserved in primary human cells.
Results
Microarray Platform and Data processing
We arrayed 405 miRNAs comprising 210 human and 49 mouse
sequences and 146 computationally predicted miRNAs from Xie
et al. [35], printed as trimeric concatemers. Previous use of
multimeric concatemers in microarray probe design [36,37] has
revealed that dimer and trimer concatemers give stronger signals
than monomers [37], and this approach has since found utility in
commercial application (Invitrogen’s nCode miRNA microarrays).
Our preliminary studies confirmed the general increase in signal of
multimeric concatemers over monomers, and also that trimers
gave stronger signals than dimers without a significant loss of
specificity (data not shown).
The microarray hybridizations were performed with Cy3-
labeled, PEG enriched small RNAs collected during a time-course
of RA- induced neural differentiation, i.e., from undifferentiated
NT2/D1 ce1ls at day 0 (NT2-undiff), after 2, 4, 6, 8, 12, 14, 21
and 28 days of the RA treatment (NT2-2D…NT2-28D) and,
subsequently from fully differentiated NT2-N neurons and NT2-A
astrocytes. Our analysis also included a comparison between NT2-
N neurons and NT2-A astrocytes and commercially available
human primary fetal neurons (PHN), fetal astrocytes (PHAf) and
embryonal astrocytes (PHAe). The complete set of expression data
is presented in Fig. S1A and have been deposited in the Gene
Expression Omnibus (GEO; http://www.ncbi.nlm.nih.gov/geo)
under accession GSE15888.
The microarray data were normalized using a median centering
procedure. This transformation resulted in a dataset that preserved
both important characteristics in the frequency distributions of
log2 intensity values (discussed below) and many large expression
differences (both up- and down-regulation) of miRNAs in the RA
time-course and in fully differentiated cells that were consistent
with the literature.
The specificity of the probes was demonstrated in hybridizations
with RNA samples, in which we were able to unequivocally
differentiate miRNAs with only single base differences, for
example hsa-miR-133a and hsa-miR-133b, and the human and
mouse forms of miR-155 (Fig. 1A). Furthermore, large differences
in signal observed between major and minor products suggested
that the microarray assay was detecting processed mature
miRNAs rather than precursor miRNAs, which contain sequence
for both major and minor products in a single RNA molecule
(Fig. 1B). Consistently, the major mature miRNA product, miR-
302a, was expressed strongly in undifferentiated NT2 cells, and
down-regulated during the RA time-course while its minor
counterpart, miR-302a*, was not expressed in any cell type.
Similarly, major product, miR-181 was strongly up-regulated
during RA treatment while the minor product, miR-181* was not
detected in any cell type.
miRNAs in Neurodevelopment
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Microarray expression data was subjected to the following three
thresholding criteria: (1) Minimum Intensity - miRNAs were
considered expressed if their normalized log2 intensity was $2 in
at least one time point; (2) Statistical Significance – miRNA
expression changes were identified using a SAM-FDR threshold of
5%; and (3) Differential Expression - a minimum 2-fold difference
in either direction was required.
We observed that, as the RA time-course progressed, the
number of miRNAs with higher intensity increased. Fig. 2A shows
the frequency distribution of the log2 intensity of human miRNAs
at various time points in the NT2-RA time-course. For all time
points the log2 intensity of the majority of miRNAs was in the 21
to 0 and 0 to 1 ranges (Fig. 2A), however, as the time-course
progressed there was an increasing number of miRNAs with log2
intensity levels .1 (39, 66, and 82 miRNAs in NT2-undiff, NT2-
8D and NT2-28D, respectively; Fig. 2B). The shift in the
distribution was more striking at higher intensity: almost three
times as many miRNAs had log2 intensity levels .2 in NT2-28D
than NT2-undiff (48 and 17, respectively; Fig. 2B).
In many cases we observed that related miRNAs, for example
major and minor products of the same precursor, and miRNAs
expressed in a polycistronic cluster, showed similar expression
profiles even though some members had log2 intensity below
threshold. For example, the polycistronic miR-302 cluster was
found to be strongly down-regulated during the RA time-course
(Fig. 3A). All of the miRNAs in this cluster passed the significance
and fold-change thresholds for down-regulation at 28 days RA,
however all of the minor products (indicated in mirBase with an
asterisk after the name) had log2 intensity below threshold
(Fig. 3A). Similarly, miR-181 family members, which are located
in three genomic clusters: mir-181a-1 and mir-181b-1 on
chromosome 1; mir-181a-2 and mir-181b-2 on chromosome 9;
and mir-181c and mir-181d on chromosome 19, were all up-
regulated during the RA time-course, but miR-181a* and miR-
181d had log2 intensity below threshold at 28 days RA (Fig. 3B).
The observed increasing trend in the number of miRNAs with
log2 intensity .1 through the RA time-course and the numerous
examples of miRNAs with low intensity values that show
agreement in expression profiles with other cluster members,
demonstrated the ability of the microarray to detect differences at
low intensity. However, in our analysis we applied a more
conservative minimum intensity threshold (i.e. log2 intensity $2)
in order to reduce the potential for false positives and focus on
miRNAs that could be said to be expressed with a high degree of
Figure 1. Specificity of microarray probes. (A) The expression patterns of miRNAs with single base differences during neural differentiation
plotted as a heatmap (top). Sequence differences are shown in bold (middle). Comparison of their expression levels in NT2-undiff and NT2-28D
plotted as yellow and blue bars, respectively (bottom). (B) The expression of major and minor mature miRNA pairs in the analyzed cells plotted as a
heatmap (top). The expression levels of the miRNA pairs in NT2-undiff and NT2-28D plotted as yellow and blue bars, respectively (bottom). The
intensity of the yellow scale in the heat map corresponds to the mean log2 expression of miRNAs on the microarrays, as shown in the key.
doi:10.1371/journal.pone.0011109.g001
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confidence. Applying this threshold in our study, 47 percent of the
human miRNAs on the microarray (99 of 210) were considered
expressed in at least one cell type.
miRNA expression profiles during the time-course of RA
treatment of NT2 cells (neurogenesis)
During RA-induced neurogenesis NT2 cells transition through
distinct temporal phases, beginning with stem cell to precursor
expansion, neural commitment and onset of cell-cycle exit (NT2-
undiff - NT2-8D), cell cycle exit and onset of neural differentiation
(NT2-8D–NT2-12D) and terminal differentiation (NT2-12D–
NT2-28D) to neurons and astroglia (NT2-N, NT2-A); hence our
data analyses focused on these time points.
Initially, only 17 human miRNAs were significantly expressed in
the stem cell state (NT2-undiff; Fig. 4), of which 11 remained
expressed throughout the RA treatment and subsequently in one
or both neural cell types. Five of the other 6 miRNAs were
members of a known ES cell specific polycistronic cluster (miR-
367, miR-302a, b, c and d) and one, miR-150, which was only
weakly expressed in NT2-undiff, were down-regulated during the
RA time-course (Fig. 4). Additionally, three minor products of the
polycistronic cluster (miR-302a*, miR-302b* and miR-302c*)
were also down-regulated, but were expressed below threshold in
NT2-undiff (Fig. 3B). Given the phasic nature of NT2 neurogen-
esis, we performed three differential expression analyses at specific
time-points of the NT2 RA treatment in order to better
characterize the miRNA expression profiles at these phases. Thus,
the comparison was made between undifferentiated state and day
8 of RA (NT2-undiff vs. NT2-8D), day 8 and 12 of RA (NT2-8D
vs. NT2-12D), and undifferentiated state and day 28 of RA (NT2-
undiff vs. NT2-28D). miRNAs meeting 3 criteria for differential
expression (expression $2, SAM-FDR#5% and fold-change $2)
were classified as up- or down-regulated with respect to the first
condition and are listed in Fig. S1B.
Precursor expansion, neural commitment and onset of
cell cycle exit
Of particular interest were 16 miRNAs that were induced within
the first 8 days of RA (Fig. 5). During this phase there is an initial
increase in expression of the intermediate filament protein nestin
(NES), peaking at 3 days of RA, indicative of a temporary pool of
proliferating neuroprogenitor cells [32]. Nestin is observed to drop
off around 6–7 days of RA treatment, with a concurrent increase in
the expression of the transcription factor neurogenic differentiation
1 (NEUROD1) characterizing the onset of exit from the cell-cycle
[32]. With the exception of miR-135a, which increased throughout
Figure 2. Distribution of human miRNAs according to microarray intensity level. (A) A histogram showing the distribution of the log2
intensity values of human miRNAs in NT2-undiff, NT2-8D and NT2-28D. (B) The data from A is tabulated to show the number of miRNAs with log2
intensity equal to or greater than specific values.
doi:10.1371/journal.pone.0011109.g002
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the RA time-course, these miRNAs showed a similar pattern of
expression, i.e., in addition to being clearly up-regulated during
early stages of neural differentiation, their expression peaked
between day 6 and day 14 of RA (Fig. 5 and Fig. S1B). Six of
these miRNAs, i.e., miR-184, miR-371-5p, miR-412, miR-219-5p,
pred-MIR145 and pred-MIR207 were expressed only during the
RA time-course (Fig. 5B). Interestingly, the 2 predicted miRNAs
(pred-MIR145 and pred-MIR207) were expressed only transiently
during the RA time-course, being detected only at days 6 and 8 of
the treatment, potentially explaining why these miRNAs have not
yet been cloned (Fig. 5B). The remaining 10 miRNAs, including 5
known (miRNAs 24, 92a, 135a, 214, and 494) and 5 predicted
(pred-MIR112, pred-MIR166, pred-MIR189, pred-MIR191, and
pred-MIR222) continued to be expressed in fully differentiated
NT2-N neurons and/or NT2-A astrocytes (Fig. 5A). Notably, of the
5 known miRNAs, miR-92a and miR-24 are both members of
described genomic miRNA clusters. Paralogs of miR-92a, are
located in the miR-17 and miR-106a genomic clusters, which we
found to be expressed predominantly in neurons, both in NT2-N
and in primary human neurons (microarray data validated by
qPCR; Fig. 6A, B & Table S1). Similarly, paralogs of miR-24 occur
in the miR-23a and miR-23b genomic clusters that were detected in
NT-A and primary human astrocytes (microarrays and/or qPCR;
Fig. 7A, B & Table S1).
One of the key steps in neurogenesis is the down-regulation of
the transcriptional repressor, RE1 silencing transcription factor
(REST), which represses neuronal mRNAs in non-neuronal cells,
including undifferentiated neural progenitors [38,39]; subsequent
loss of REST repression then drives cells towards commitment to a
neural phenotype. As such, miRNAs up-regulated in the first 8
days of RA, just prior to the down-regulation of REST [34], are
good candidates as REST targeting miRNAs. Using miRanda [40]
we searched the 39-UTR of human, mouse and dog REST for
conserved putative miRNA recognition elements (MREs) of the
subset of miRNAs up-regulated in the first 8 days of RA treatment.
We identified MREs for two miRNAs conserved in human and
dog (miR-135a and miR-371-5p), one conserved in human and
mouse (miR-494) and four conserved in human, mouse and dog
(miR-92a, miR-219-5p, pred-MIR145 and pred-MIR207; Fig. 5).
The miR-219-5p MRE was of particular interest as this miRNA
was immediately and robustly up-regulated on addition of RA. At
2, 4, 6 and 8 days RA versus NT2-undiff, miR-219-5p showed 7,
12, 40 and 54-fold up-regulation, respectively. Furthermore, from
Day 6 through Day 14, this miRNA showed the highest intensity
of all miRNAs on the array. The identification of these elements,
together with their conservation across species and described
expression dynamics, suggest these miRNAs may well be good
candidates for the regulation of REST expression.
Figure 3. Microarray sensitivity. The expression levels of the members of the miR-302 (A) and the miR-181 (B) genomic clusters during neural
differentiation plotted as heatmaps (top panels). The expression levels of the same miR-302 (A; bottom left panel) and miR-181 (B; bottom right
panel) genomic clusters in NT2-undiff and NT2-28D plotted as yellow and blue bars, respectively. The intensity of the yellow scale in the heat map
corresponds to the mean log2 expression of miRNAs on the microarrays, as shown in the key on Figure 1.
doi:10.1371/journal.pone.0011109.g003
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Cell-cycle exit and onset of neural differentiation
Between 8 and 12 days of the NT2 RA time-course nestin
expression continues to decline whilst NEUROD1 is robustly
expressed [32]. By the end of this period most cells have exited the
cell cycle and are committed to differentiate to a neural phenotype, as
evidenced by a drop in the percentage of BrdU and Ki67 positive
cells and the emergence of MAP2 positive cells [32,33]. In these cells,
this phase follows the down-regulation of REST, which has been
shown to repress transcription of a number of neural miRNAs
including miR-124, miR-9, miR-21, miR-106b and miR-93 [16,41].
During this phase 18 miRNAs were up-regulated (Fig. 8), including
the above mentioned REST target miRNAs and miR-133a, a likely
REST target that is up-regulated during differentiation of human
HSF6 ESCs to neurons [42,43]. In addition we identified 7 putative
REST repressed genes by their proximity to predicted and/or
chromatin immunoprecipitated (ChIP) RE-1 elements (Table 1).
Figure 4. Profiles of humanmiRNAs expressed in the stem cell state of NT2 cells (NT2-undiff). The intensity of the yellow scale in the heat
map corresponds to the mean log2 expression of miRNAs on the microarrays, as shown in the key on Figure 1.
doi:10.1371/journal.pone.0011109.g004
Figure 5. Expression profiles of miRNAs induced within the first 8 days of the RA treatment. (A) Subset of miRNAs induced during 8 days
of RA treatment and subsequently expressed in NT2-derived differentiated cells. (B) Subset of miRNAs expressed transiently during the RA time-
course, but not detected in either NT2-derived or human primary differentiated cells. Indicated are miRNAs for which MREs were found in the 39UTR
of human REST and conserved in mouse (m), and/or dog (d),62 indicates that 2 conserved MREs were found. The intensity of the yellow scale in the
heat map corresponds to the mean log2 expression of miRNAs on the microarrays, as shown in the key on Figure 1.
doi:10.1371/journal.pone.0011109.g005
miRNAs in Neurodevelopment
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Figure 6. Expression of neuronal miRNAs in genomic clusters. Expression of 3 related genomic clusters containing predominantly neuronal
miRNAs; the miR-17 cluster (A), the miR-106a cluster (B) and the miR-106b cluster (C). Each cluster is plotted as a heatmap; and as a bar graph which
shows the expression level of the miRNAs in PHAf and PHN plotted in yellow and blue, respectively. The intensity of the yellow scale in the heat map
corresponds to the mean log2 expression of miRNAs on the microarrays, as shown in the key on Figure 1.
doi:10.1371/journal.pone.0011109.g006
miRNAs in Neurodevelopment
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Figure 7. Expression of astrocytic miRNAs in genomic clusters. Expression of 3 genomic clusters containing predominantly astrocytic
miRNAs; the miR-23a cluster (A), the miR-23b cluster (B) and the miR-29a cluster (C). Each cluster is plotted as a heatmap; and as a bar graph which
shows the expression level of the miRNAs in PHAf and PHN plotted in yellow and blue, respectively. The intensity of the yellow scale in the heat map
corresponds to the mean log2 expression of miRNAs on the microarrays, as shown in the key on Figure 1.
doi:10.1371/journal.pone.0011109.g007
miRNAs in Neurodevelopment
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Interestingly, most of the miRNAs differentially expressed between 8
and 12 days RA were also found to be differentially expressed in
primary human neurons and astrocytes, including all 6 known, and 4
putative REST regulated miRNAs; miR-21 was astrocytic and the
other 9 were neuronal (Fig. 8). Furthermore, while some of these
miRNAs, including miR-124, were expressed above threshold earlier
in the time-course, none of them were significantly induced within the
first 8 days of RA suggesting that loss of REST may be required for
induction of these miRNAs.
Neuronal and astrocytic miRNA profiles (terminal
differentiation)
At 28 days of RA treatment the NT2 cell cultures contained
both neurons and astrocytes and the miRNA expression pattern at
this time point represented this mixed population of cells. In order
to establish the cell-type specific patterns we performed miRNA
expression profiling on cultures of pure NT2-N neurons expressing
neuron-specific enolase (ENO2) and NT2-A astrocytes expressing
GFAP produced using a protocol established in our laboratory
[32,44]. Using the same criteria as for the RA treatment time-
course (expression $2, SAM-FDR#5% and fold-change $2),
miRNA expression of the pure cell populations was compared to
28 Day RA treated NT2 cells (NT2-28D vs. NT2-N and NT2-
28D vs. NT2-A) and miRNAs meeting these criteria were
classified as higher or lower with respect to NT2-28D. We also
compared the cells to each other (NT2-N vs. NT2-A) and classified
the miRNAs as neuronal or astrocytic based on their relative
expression. The data is summarized in Fig. S1C.
The comparisons revealed that the expression of 26 miRNAs
was higher in NT2-N as compared to NT2-28D of RA, whereas
13 miRNAs showed a lower expression level. The opposite trend
was observed in NT2-A in which the expression of 40 miRNAs
was lower and only 13 was higher in comparison to NT2-28D. We
found that the expression of miRNAs labeled as astrocytic (from
the NT2-A vs. NT2-N comparison) was in all cases but one, higher
in NT2-A than NT2-28D, whereas the expression of the majority
of neuronal miRNAs (13 of 17) was lower in NT2-A compared to
NT2-28D. In general, all miRNAs classified as neuronal or
astrocytic in the NT2-N vs. NT2-A comparison were also
differentially expressed in one, or both differentiated cells data
sets in comparison with NT2-28D (Fig. S1C). Interestingly, 15 of
17 miRNAs labeled neuronal, but only 1 (miR-21) of 10 astrocytic
were up-regulated during the 28 Day RA time-course (Fig. S1A).
Comparison between primary and NT2-derived human
neurons and astrocytes
To further characterize the miRNA profiles of human neurons and
astroglia we performed 2 comparative analyses of differential
expression in PHAf vs. PHN and PHAe vs. PHN using the same
criteria as for the time-course of NT2 cells RA treatment. These data
sets were subsequently compared with the NT2-A vs. NT2-N set. The
miRNAs meeting all criteria (expression $2, SAM-FDR#5% and
fold-change$2) were labeled as astrocytic or neuronal based on their
relative expression. The data is summarized in Fig. S1D.
We identified 49 neuronal and 14 astrocytic miRNAs from the
comparison of their expression in PHAf vs. PHN. Of these, 21
neuronal and 10 astrocytic miRNAs met the screening criteria in
PHAe vs. PHN, and 11 neuronal and 10 astrocytic in NT2-A vs.
NT2-N. Four miRNAs (miR-27a, miR-27b, miR-24, and miR-
29a), although classified astrocytic in primary cells, passed the ratio
threshold, but failed either the expression level or SAM-FDR
threshold criteria in NT2-A vs. NT2-N. The astrocytic expression
Figure 8. Expression profiles of miRNAs induced between 8 and 12 days of the RA treatment. Subset of miRNAs induced between 8 and
12 days of RA treatment. Indicated are miRNAs containing known or putative RE-1 sites and miRNAs labeled as Neuronal or Astrocytic based on the
comparison between human primary neurons with primary astrocytes (PHN vs. PHAf). The intensity of the yellow scale in the heat map corresponds
to the mean log2 expression of miRNAs on the microarrays, as shown in the key on Figure 1.
doi:10.1371/journal.pone.0011109.g008
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of miR-24 and miR-27a, however, was confirmed by qPCR (Table
S1). miR-24 and miR-27a are members of a genomic cluster on
chromosome 19 with the astrocytic miRNA miR-23a (Fig. 7A). A
paralogous miR-24 gene is found on chromosome 9 with miR-27b
and the astrocytic miRNA miR-23b (Fig. 7B). miR-29a is clustered
with the astrocytic miRNA miR-29b on chromosome 7 (Fig. 7C).
This suggested that members of these clusters are astrocytic in
both NT2-A and primary human cells.
Of the 49 neuronal miRNAs identified in primary human
neurons, 27 passed the ratio threshold in NT2-N vs. NT2-A and
similarly 12 of 17 NT2 neuronal miRNAs passed the ratio
threshold in PHN vs. PHAf cells. Interestingly, all 49 neuronal
miRNAs were more strongly expressed in PHAe than in PHAf.
Among the 49 neuronal miRNAs in primary human neurons were
members of 3 related genomic clusters; 4 members of the miR-17
cluster on chromosome 13 (miRNAs 17, 19a, 19b, and 20a;
Fig. 6A), 3 members of the miR-106a cluster on chromosome X
(miRNAs 19b, 20b, and 106a; Fig. 6B) and 2 members of the miR-
106b cluster on chromosome 7 (miRNAs 106b and 93; Fig. 6C).
All of the members of these clusters showed higher expression in
PHN than PHAf (Fig. 6A,B,C). In general, not all astrocytic and
neuronal miRNAs (classified based on their expression in primary
cultures) were expressed at 28 days RA treatment of NT2 cells, but
most of them were expressed in pure populations of NT2-A (93%)
and NT2-N (63%) cells (Fig. S1A). Thus, for the most part, NT2-A
astrocytic miRNAs were also astrocytic in primary human cells
and, similarly, miRNAs labeled neuronal in NT2-N were also
neuronal in their primary human counterparts.
Validation of microarray data by qPCR
Validation of the microarray results for known miRNAs was
carried out by real-time qPCR using a TaqMan miRNA assay.
qPCR was performed on a selection of the miRNAs identified as
differentially expressed by microarrays (from comparisons of
undifferentiated NT2 cells at day 0 with those at day 8, 14, 21
or 28 of RA treatment; primary human neurons and fetal
astrocytes; primary human neurons and embryonic astrocytes; and
NT2 neurons and astrocytes). Additionally, a number of miRNAs
that failed one or more threshold criteria on the microarrays were
also examined by qPCR and were found to be differentially
expressed. Overall over 90 percent of the miRNA microarray
results tested were validated by qPCR, confirming the integrity of
the data generated by the microarray platform. Extensive
validation details are provided in Table S1.
Identification of predicted miRNAs by qPCR and
amplicon sequencing
Since this study was undertaken a number of the predicted
miRNAs from Xie et al. [35] have subsequently been confirmed
by others and already appear in miRBase (indicated in Table
S1A), but many still remain unidentified. We selected 6 predicted
miRNAs (pred-MIR112, 145, 189, 191, 207 and 222) that have
not yet been identified either in vitro or in vivo in any species, but
were clearly expressed on our microarrays, and used nCode
microRNA real-time qPCR to confirm their expression in human
cells. We performed a qualitative analysis of the qPCR dissociation
profiles and separated PCR products by agarose electrophoresis to
identify visible bands generated during the qPCR reactions.
Additionally, 2 known miRNAs, miR-10a and miR-302a, were
used as controls for up- and down-regulation, respectively. The
PCR primers and annealing temperatures used are provided in
Table 2. The differential expression of the control miRNAs
obtained using the nCode real-time qPCR method agreed with
both the microarray and TaqMan real-time qPCR results (Fig. 9).
Furthermore, we were able to amplify 2 of the predicted miRNAs,
i.e., pred-MIR191 and pred-MIR222, using primers 2 and 3,
respectively, at an annealing temperature of 60uC (Table 2). The
PCR amplified bands, observed for both pred-MIR191 and pred-
MIR222, were cut from the gel and the sequences were then
validated by cloning and sequencing of the amplicons. The mature
sequences of these miRNAs were determined to be: pred-MIR191;
59-AGCAGGTGCGGGGCGGCG-39 and pred-MIR222; 59-
CAGTGCAAGTGTAGATGCCGA-39. The predicted miRNAs,
pred-MIR191 and pred-MIR222, were submitted to miRBase
(http://www.mirbase.org/) and have been assigned the names
hsa-miR-3665 and hsa-miR-3666, respectively.
Table 1. RE-1 sites near miRNAs.
miRNA
RE-1
distance (kbp)
Human
ChIP-Seq
Score in
RE-1db
miR-9-1 2238.0 Yes 0.962
5.7 Yes 0.9628
mir-9-2 213.8 Yes 0.9523
213.9 Yes 0.8925
miR-9-3 3.0 Yes 0.9426
6.1 Yes
miR-21 298.6 Yes
miR-124-1 246.6 Yes
221.7 Yes 0.9237
miR-124-2 0.8 Yes 0.981
2108.5 No 0.9357
261.9 No 0.9645
22.4 Yes 0.9108
mir-124-3 0.4 No 0.9583
200.2 Yes 0.8986
283.0 No 0.9177
474.7 No 0.9223
2333.1 Yes 0.9584
miR-1-1/miR-133a-2 12.0 Yes
22.9 No 0.9398
miR-93/106b No
miR-20a (miR-17 cluster) 292.3 Yes 0.9095
miR-103-1 32.0 Yes 0.9364
miR-103-2 2130.0 Yes
miR-138-1 22.3 Yes
418.7 Yes 0.928
miR-181a-2/b-2 2276.8 Yes
77.5 Yes
miR-181c/d 2433.0 Yes 0.9669
2411.0 Yes 0.9645
miR-301a 239.4 No 0.9128
395.0 Yes
Known and putative RE-1 sites regulating miRNAs were identified by aligning
the genomic locations of human miRNAs from miRBase, obtained from the
UCSC human genome browser (hg17) sno/miRNA track, with putative REST
sites from the human RE-1db [56] and data from a ChIP-Seq analysis for REST in
human K562 cells [42]. RE-1 sites were associated with a miRNA if they were less
than 500kbp away and found either in the ChiP-Seq data or in RE-1db mkII with
a PSSM score greater than 0.91.
doi:10.1371/journal.pone.0011109.t001
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Both pred-MIR191 and pred-MIR222 are associated with host
genes suggesting that, potentially, their expression could be co-
regulated. Thus, pred-MIR191 lies 219bp upstream of and
antisense to SLAIN1 (SLAIN motif family, member 1), a gene
strongly expressed in human embryonic stem cells and down-
regulated during differentiation, but expressed in the brain [45].
Similarly, pred-MIR222 is in an intron of FOXP2 (forkhead box
P2), a transcription factor expressed during embryogenesis and
thought to be involved in development of motor-related circuits in
mammalian brain [46]. We compared the expression of these
genes at day 0 and day 8 of the RA-treatment. The results showed
that both pred-MIR191 and its host gene SLAIN1 were up-
regulated after 8 days RA (Fig. 9; NT2-8D/NT2-undiff: pred-
MIR191 - 2.3-fold, p0.04 and SLAIN1- 5.9-fold, p0.1). We also
confirmed the co-expression of FOXP2 and pred-MIR222 at day 0
and day 8 of RA (Fig. 9; NT2-8D/NT2-undiff: FOXP2 - 2.1-fold,
p0.02 and pred-MIR222 - 1.4-fold, p0.1).
Discussion
We performed a comprehensive analysis of miRNA expression
patterns during RA-induced differentiation of human NT2 cells.
This well characterized cell system is a valuable in vitro model of
neurogenesis, in which these ‘‘surrogate’’ stem cells undergo, in
response to RA treatment, expansion of precursor pool, neural fate
commitment and terminal differentiation to neurons and astroglia
[32,33,47,48]. Using this model we were able to identify distinct
subsets of miRNAs associated with different developmental
stages suggesting their role in molecular pathways critical for
neurodevelopment.
Validity of experimental model
A number of observations arising from our data would appear
to support suitability of our experimental approach and the
choice of NT2 cell system to study the function of miRNAs in
neurogenesis. Firstly, greater than 90% of microarray expression
data was validated by qPCR, indicating that the methodology
used is not subject to a notable degree of false positive/negative
signals. Furthermore, a number of the miRNAs we identified as
induced by RA are consistent with those RA-induced miRNAs
previously reported by Sempere et al. [26] (Fig. S1A). Moreover,
the undifferentiated NT2 cells expressed members of ES cell
specific polycistronic cluster (miR-367, miR-302a, b, c and d),
Table 2. PCR confirmation of predicted miRNAs.
Gene Primer Primer Sequence 59-39 Anneal temp (uC)
10a 1 TACCCTGTAGATCCGAATTTGTG 57
10a 1 TACCCTGTAGATCCGAATTTGTG 58.5
302a 1 TAAGTGCTTCCATGTTTTGGTGA 57
302a 1 TAAGTGCTTCCATGTTTTGGTGA 60
pred-MIR112 1 GGACACAGTGGCACGGGGTGGC 57
pred-MIR112 2 ACACAGTGGCACGGGGTGGCAA 57
pred-MIR112 3 ACACAGTGGCACGGGGTGGC 57
pred-MIR145 1 TTTAAATGGGCCACCCTGTAAA 57
pred-MIR145 1 TTTAAATGGGCCACCCTGTAAA 58.5
pred-MIR145 1 TTTAAATGGGCCACCCTGTAAA 60
pred-MIR189 1 TGCTGGTGAGGGAGCCCTGCTG 57
pred-MIR191 1 CAGCAGCAGGTGCGGGGCGGCG 60
pred-MIR191 2 AGCAGGTGCGGGGCGGCGAAA 57
pred-MIR191 2 AGCAGGTGCGGGGCGGCGAAA 60
pred-MIR191 3 AGCAGCAGGTGCGGGGCGGCGA 60
pred-MIR207 1 ACTTTGTGCTGGTGCCGGGGAA 57
pred-MIR222 1 CAGTGCAAGTGTAGATGCCGAC 57
pred-MIR222 1 CAGTGCAAGTGTAGATGCCGAC 58.5
pred-MIR222 1 CAGTGCAAGTGTAGATGCCGAC 60
pred-MIR222 2 CAGTGCAAGTGTAGATGCCGA 57
pred-MIR222 2 CAGTGCAAGTGTAGATGCCGA 60
pred-MIR222 3 CAGTGCAAGTGTAGATGCCGAAA 57
pred-MIR222 3 CAGTGCAAGTGTAGATGCCGAAA 60
pred-MIR222 4 GTGCAAGTGTAGATGCCGACAA 57
pred-MIR222 4 GTGCAAGTGTAGATGCCGACAA 60
SLAIN1 Forward TTCACCTCAAGCCCAAACTC 60
Reverse TGACTATTTCGCACGGTGAC
FOXP2 Forward ATTGGATGACCGAAGCACTG 60
Reverse GTGCAAGTGGGTCATCATTG
Note: Primers and conditions used for sequencing of the predicted miRNAs are bolded.
doi:10.1371/journal.pone.0011109.t002
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consistent with their stem cell properties [29,30], which,
subsequently, were down-regulated as the RA time-course
progressed and the cells acquired the neural precursor features
[32,34]. Notably, the expression of this cluster is regulated by the
transcription factor POU5F1, which is down-regulated upon
addition of RA to NT2 cells [34,49,50]. Finally, and most
importantly, there was a very good agreement regarding miRNA
data sets generated using the NT2-derived cells and human
primary neurons and astrocytes, confirming that NT2 cells
represent an accessible and reproducible model of human neural
development.
A number of miRNAs expressed on our microarrays have been
characterized in the literature and linked to the process of
neurogenesis (Fig. S2) [51]. One example is miR-124, which once
released from repression by REST, is particularly important in
determining neural cell fate via regulation of Sox9 [12,16], and
which we also found to be neuronal in both NT2 and primary
human neurons. Another is miR-23, which, in agreement with the
report of Smirnova et al. [11], was preferentially expressed in
astrocytes. Similarly, the let-7 miRNAs, reported to be promi-
nently up-regulated in neurogenesis by Krichevsky et al. and
Smirnova et al. [10,11], showed clear neuronal expression in both
NT2-N and primary human neurons. In our experiments the
expression of at least two let-7 members (let-7b and let-7f)
increased during the 28 day time-course. We also detected
expression of a number of miRNAs associated with neurological
disorders, such as miR-29 and miR-107 associated with Alzhei-
mer’s disease [20,21].
Taken together, the changes in miRNA expression profiles
observed during RA-induced differentiation of NT2 cells could be
considered to reflect their involvement in different stages of
human neurodevelopment. Therefore, NT2 cells represent a
convenient experimental system amenable to future mechanistic
studies required to elucidate specific functions of miRNAs in
neurogenesis.
Implications for neurodevelopment
A preliminary analysis of the microarray data revealed an
increase in the number of miRNAs expressed as the RA time-
course progressed (Fig. 2), in agreement with the progressive, non-
restrictive model of miRNA expression in which there is a trend to
increased miRNA expression signature with developmental state
[52]. We have identified two subsets of miRNAs with potential
functional significance for the process of neurogenesis. These were
16 miRNAs that were up-regulated early in the RA time-course
and which, in all cases but one, peaked in expression between day
6 and 14 of RA treatment (Fig. 5) and 18 miRNAs, which were
induced between 8 and 12 days of RA (Fig. 8). We proposed that
these subsets were of particular biological significance, as these
would act early in the differentiation process and might play a role
in cell-fate determination and maintenance of differentiated state
as they were expressed prior to, and during the cell cycle exit of
neural precursors, respectively [32].
In the first 8 days of the NT2-RA time-course, REST is down-
regulated, allowing the expression of a number of neuronal genes
and committing cells to a neural phenotype [34,53]. Although
miR-9 has been shown to down-regulate REST via MREs in the
REST 39-UTR it is also repressed by REST [16,19]. Since, in our
NT2-RA time-course, the decrease in REST expression preceded
the increase in expression of miR-9 we investigated whether other
miRNAs, which increased in the first 8 days, may target REST
(Fig. 5). We identified a number of miRNAs with conserved MREs
(Fig. 5). Perhaps the most interesting was a highly conserved MRE
in the REST 39-UTR for miR-219-5p, the most strongly up-
regulated of all miRNAs during the first 8 days of RA treatment.
This miRNA is expressed early in development, and its
dysregulation leads to embryonic defects in zebrafish [54].
Furthermore, using miRanda [40], we identified an MRE for
dre-miR-219 in the zebrafish genomic sequence (danRer5),
approximately 3 kbp downstream of the REST coding region
(i.e. within the putative zebrafish REST 39-UTR). Taken together
Figure 9. Real-time qPCR analysis of predicted miRNAs and associated host gene mRNAs. Fold change values are means of n replicates (n
as indicated), and p-values are derived from 2-tailed student’s t-tests. Error bars are derived from the S.E.M. of the DCT values (average fold
change6(2SEM21)). The grey bars are NT2-8D/NT2-undiff and the white bar is NT2-28D/NT2-undiff. As there was no amplification of miR-10a in NT2-
undiff a value of 40 cycles was used to compute the DCT values.
doi:10.1371/journal.pone.0011109.g009
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this suggests an important role for this miRNA in development
that may involve the regulation of REST. We observed a large
increase in the number of miRNAs expressed at 12 days RA and
many of these miRNAs were significantly up-regulated between 8
and 12 days including the REST regulated miRNAs miR-9 and
miR-124, which play important roles in neurogenesis [9,10,14,16]
and miR-21, which has been proposed as a suppressor of
pluripotency in embryonic stem cells [41] (Fig. 8). Using a
combination of data from a genome-wide ChIP-Seq analysis for
REST in human K562 cells and predicted sites from the human
RE-1db (http://www.bioinformatics.leeds.ac.uk/RE1db_mkII/)
[42,55,56] we identified a number of other candidate REST
regulated miRNAs (Fig. 8 and Table 2). With the exception of
miR-301, all of these putative REST target miRNAs were found to
be expressed in both NT2-N and PHN, and many of them were
differentially expressed between neurons and astrocytes suggesting
that they may be regulators of neuronal development and function
(Fig. 8).
Previously our group has characterized gene expression patterns
during the RA induced neurogenesis of NT2 cells and identified
sets of genes considered significant for cell cycle regulation and
differentiation [34]. Here we observed that many of these
differentiation related genes were predicted targets for a number
of the miRNAs up-regulated during this time frame based on a
comparison of our miRNA profiles with the Microcosm Targets
database (http://www.ebi.ac.uk/enright-srv/microcosm/htdocs/
targets/v5/). Whilst these target sites are predicted and currently
remain un-tested, the comparisons between the mRNA and
miRNA expression data sets may provide a fast screening method
for selection of candidate miRNA/target pairs for further direct
functional analysis. For example, a number of HOX genes that are
down-regulated during neurogenesis contain predicted binding
sites for miRNAs expressed after 12 days of RA treatment.
Interestingly, the interaction between the neuronal miR-10a and
HOXA1 gene, has already been experimentally verified [57]. Cell
cycle exit is also characterized by a decrease in the expression of
cyclins [34]. Therefore, miRNAs expressed after 12 days RA,
particularly those expressed in post-mitotic neurons, such as miR-
10a, 10b, 20a, 181a and let-7b, which are predicted to target
cyclin genes, would be excellent candidates for further functional
analyses. One of these miRNAs, let-7b, has recently been shown to
target cyclin genes D1, D3, and A1, and cyclin-dependent kinase
CDK4, in-vitro [58].
The comparisons of expression profiles between human primary
and NT2-derived cells revealed miRNAs that might play a role in
the development and maintenance of differentiated neurons and
astrocytes. Thus, miRNAs expressed in primary human astrocytes
showed different expression profiles to miRNAs expressed in
primary human neurons and during the differentiation and
maturation of NT2 cells. Notably, far fewer miRNAs were
expressed in astrocytic than in neuronal cells suggesting that a
higher complexity of gene expression regulation exists in post-
mitotic neurons than in proliferation competent astrocytes. This is
consistent with previous reports suggesting that larger numbers of
miRNAs are expressed in differentiated and higher specialized
cells such as neurons [51,52]. The miRNAs found to be expressed
in both astrocytes and neurons are perhaps involved in
maintenance of the terminally differentiated state in both cell
types. For example, miR-24, which we found up-regulated early
during the differentiation process and subsequently expressed in
both astrocytes and neurons, is known to target dihydrofolate
reductase (DHFR) [59], a gene critical for DNA synthesis and
replication; suggesting that miR-24 may play a role in cellular
differentiation via targeting of DHFR to inhibit DNA replication.
This, again, is consistent with the reported down-regulation of
DHFR in terminally differentiated neurons [60].
Validation of predicted miRNAs
One impediment to successful amplification of the predicted
miRNAs is that the exact position and length of the mature
product within the pre-miRNA is not known, and cannot be
accurately predicted using currently available tools. The predicted
mature miRNA sequences identified by Xie et al. [35] were
determined computationally and all of their mature miRNAs were
reported as 22 nt sequences. A number of the pre-miRNA and
mature miRNA sequences appearing in miRBase differ from those
predicted by Xie et al. [35] and in fact the mature sequence of
many other miRBase entries have been modified and updated as
new data is provided. Another impediment is that successful
amplification with the nCode system sometimes requires modifi-
cations to the miRNA specific forward primer to improve
amplification, including removing bases to lower Tm and/or
adding 39-adenines to improve specificity. It was for this reason
that we also used amplicon sequencing, and from this combination
of data we derived the mature sequences. The amplicon sequences
of both predicted miRNAs differed from those reported by Xie et
al. [35]. Pred-MIR191 was determined to be 18 nt, omitting 4 nt
at the 59 end and pred-MIR222 was 21 nt, missing 1 nt at the 39
end. In addition we also tested the expression of the predicted
miRNAs, pred-MIR191 and pred-MIR222, and the associated
host genes, SLAIN1 and FOXP2, and demonstrated that they
followed the same kinetics. This, in turn, raised an interesting
possibility that the region between SLAIN1 and pred-MIR191,
which contains both a putative promoter and a CpG island, may
be responsible for co-regulation of these genes through a bi-
directional promoter mechanism [61]. Furthermore the presence
of a predicted binding site for pred-MIR191 in the 39-UTR of
SLAIN1 also raises the possibility that this miRNA can regulate the
translation of its host gene, a mechanism that has been proposed
for miR-186 in dog [62] and for miR-763 in human, mouse and
rat [63].
Conclusions
We present what is currently the most comprehensive analysis of
miRNA expression using a reproducible experimental model of
human neural differentiation, upon which the further mechanistic
studies required to establish the roles of miRNAs during neural
development can be performed. This knowledge, in combination
with identification of specific miRNA targets, will ultimately reveal
the metabolic pathways that they control and bring about better
understanding of molecular mechanisms controlling the process of
neurogenesis.
Materials and Methods
Cell Culture
Time-course of retinoic acid treatment. Human em-
bryonal teratocarcinoma NTera2/D1 (NT2) cells (Stratagene, La
Jolla, CA) were cultured in high glucose Dulbecco’s modified
Eagle’s medium (HG/DMEM, Invitrogen, Burlington, Ontario,
Canada) supplemented with 10% fetal bovine serum (FBS, Wisent,
Saint-Jean, Quebec, Canada) and differentiated with all-trans
retinoic acid (RA, Sigma, Oakville, Ontario, Canada) as previously
described [33]. Briefly, cells were seeded at a density of 26106
cells per T-75 flask and treated with 10mM RA for 28 days added
with fresh medium every two days. Cells were harvested for RNA
extraction at 0, 2, 4, 6, 8, 12, 14, 21, and 28 days of the RA
treatment. The time-course experiments were repeated several
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times to provide multiple biological replicates for microarray
analysis.
Generation of NT2-N neurons and NT2-A astro-
cytes. Pure NT2-N neurons were isolated from 28-day RA-
treated cultures as previously described [44]. Briefly, the RA-
treated cells were trypsinized, re-plated at a 1:6 dilution in new T-
75 flasks and cultured for 9 days in RA-free HG/DMEM
supplemented with 5% FBS and mitotic inhibitors (1mM cytosine
b-D-arabinofuranoside, 10mM uridine, and 10mM 5-Fluoro-
29deoxyuridine). The NT2-N neurons, growing on the top of
underlying astrocytes (NT2-A), were separated by gentle
trypsinization (0.015% v/v) and mechanical shake-off. The
neurons were re-plated on poly-D-lysine and Matrigel-coated T-
25 flasks (26106 cells/flask) and maintained for an additional 7
days in a 50:50 mix of NT2-A -conditioned medium and fresh
DMEM with 10% FBS before being harvested for RNA
extraction.
Pure NT2-A astrocytes were also generated from 28-day RA-
treated cultures after the removal of neurons. Briefly, the RA-
treated cells were grown overnight in RA-free HG/DMEM
supplemented with 5% FBS and weakly attached neurons were
removed by gentle trypsinization (0.015% v/v) and mechanical
shake-off leaving the astrocytic cells in the flask. This step was
repeated and the remaining NT2-A cells were maintained in HG/
DMEM and 5% FBS with medium changed twice a week. Cells
were subcultured when confluent. Total RNA was extracted from
2 to 8 weeks old NT2-A cultures.
Primary human neurons and astrocytes. Fresh primary human
neurons (PHN) from 21 week fetuses were obtained from
ScienCell Research Laboratories (Carlsbad, CA) and were directly
pelleted for RNA extraction.
Frozen primary human fetal astrocytes (PHAf) from 20–21 week
fetuses were received from ALLCELLS (Emeryville, CA) and were
cultured in Astrocyte Medium provided by the company.
Frozen primary human embryonal astrocytes (PHAe) from 9–10
week embryos were received from StemCell Technologies
(Vancouver, BC, Canada) and were cultured as recommended
by the supplier and harvested for RNA extraction. Cell
populations were expanded and then harvested for RNA
extraction.
All of the human cells used in this study were obtained in
accordance with principles embodied in the Declaration of
Helsinki (Code of Ethics of the World Medical Association).
RNA Extraction
Total RNA was isolated from the cells using TRI-Reagent
(Molecular Research Center, Cincinnati, OH) according to the
manufacturer’s instructions. High molecular-weight RNAs were
removed by precipitation with 12.5% PEG-8000 and 1.25 M
NaCl using the method of Thompson et al. [64].
Microarray Platform
Oligonucleotide probes for 405 miRNAs, synthesized by MWG-
Biotech (High Point, NC) and Sigma-Genosys (Saint Louis, MO),
were resuspended in Nexterion Spot II buffer (Schott Nexterion,
Louisville, KY) at a concentration of 40mM and printed in
triplicate onto Nexterion Slide E epoxy-coated glass slides with an
Affymetrix 417 Arrayer (Affymetrix, Santa Clara, CA) in a pattern
of four 20618 sub-arrays with 350mm spacing between spots. The
spotted ‘‘trimeric concatemer’’ probes were complementary to the
mature miRNA sequences concatenated three times, such that a
22 nt miRNA was represented on the array by a 66 nt probe.
Sequences for 210 human and 49 mouse miRNAs were obtained
from miRBase version 5.1. All miRNA names and accession
numbers were updated to miRBase 14.0 (Fig. S1A). Sequences for
an additional 146 computationally-predicted miRNAs were
obtained from Xie et al. [35]. Of these, 36 were subsequently
identified as human miRNAs in miRBase version 14.0 (Fig S1A).
Probes for U6 RNA and five human and two mouse tRNAs were
spotted as positive controls. Negative controls were three
sequences with no sequence similarity to any known mammalian
miRNAs [65]. The M13-reverse universal sequencing primer was
used as a control for specificity of hybridization. For intra-assay
validation, the standard deviation calculated for miRNA triplicates
was ,10% for the vast majority (.99%) of oligos. Furthermore,
we collected NT2 cells from several independent experiments such
that most time-points in the neural differentiation time-course
represented at least three biological replicates which were
averaged to arrive at the final expression levels reported. 25 mg
of RNA was utilized for the time-course experiments, and 10 mg
for the neuron and astrocyte experiments.
RNA Labeling and Microarray Hybridization
RNA labeling and hybridization to the microarrays was carried
out using a method adapted from Thompson et al. [64]. Briefly, 10
or 25 mg total RNA was PEG-precipitated (as above), resuspended
in 6 ml water, and mixed into a labeling reaction (final
volume 10 ml) consisting of 500 ng 59-phophate-cytidyl-uridyl-
Cy3-39 (Dharmacon, Chicago, IL), 10% DMSO, 0.1 mM ATP,
50 mM HEPES (pH 7.8), 3.5 mM DTT, 20 mM MgCl2, 0.1 mg
BSA, and 20 U T4 RNA ligase (NEB, Ipswitch, MA). Reactions
were incubated on ice in the dark for 2 hours before precipitation
with 0.27 M sodium acetate, 20 mg glycogen, and 2.7 volumes
ethanol in a 200 ml final volume. Following 10 min incubation on
ice and 10 min centrifugation, the pellet was washed in 70%
ethanol, centrifuged 5 min, briefly dried, and resuspended in 6 ml
water. Labeled RNA samples were hybridized to microarrays in a
35 ml final volume composed of 400 mM Na2HPO4 (pH 7.0), 5%
SDS, 0.8% BSA, and 12% formamide. Hybridization mixtures
were denatured at 95uC for 4 minutes and immediately pipetted
onto glass slides covered with 22625 mm LifterSlips (Erie
Scientific Company, Portsmouth, NH). Hybridizations were
performed in custom-made sealed chambers submerged in a
37uC water bath overnight (18 hours). Slide washes were 3 min
long: once in 26SSC/0.025% SDS, three times in 0.86SSC, and
twice in cold 0.46SSC. Immediately following the last wash, slides
were dried by centrifugation and scanned with a ScanArray
5000XL (Packard BioScience, Meriden, CT) confocal scanner at
10 mm resolution.
Microarray Data Analysis
Microarray scans were analyzed with QuantArray software
version 3.0 (Packard BioScience, Meriden, CT) using an adaptive
quantitation method. Spots of poor quality on the arrays were
flagged for removal from the data processing. Cy3 mean pixel
intensities were background subtracted, log transformed, and
replicate probes on the arrays were averaged. The intensities of
each unique probe, including positive and negative controls, were
normalized by subtracting the median log2 intensity of all unique
probes on the array, thus median centering all of the arrays to
zero. miRNAs were considered expressed if their normalized log2
intensity was $2. Differentially-expressed miRNAs were identified
using a SAM-FDR (Significance Analysis of Microarrays-False
Discovery Rate [66] threshold of 5% and a fold-change of 2 in
either direction. The microarray data are MIAME compliant and
have been deposited in the Gene Expression Omnibus (GEO;
http://www.ncbi.nlm.nih.gov/geo) under accession GSE15888.
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Real-time qPCR of known miRNAs
Real-time qPCR assays for known miRNAs were carried out
using the TaqManH Human MicroRNA Assay (Applied Biosys-
tems, Foster City, CA). Briefly, 10 ng total RNA was reverse
transcribed in 15 ml reactions containing 3.33 U MultiScribe
reverse transcriptase, 0.25 U RNase inhibitor, 1 mM dNTPs, and
3 ml of the provided miRNA-specific looped RT primer. Reactions
were incubated at 16uC for 30 min, 42uC for 30 min, and 85uC
for 5 min. PCR reactions of 20 ml were prepared with 1.4 ml of the
RT reaction product, TaqMan 26Universal PCR Master Mix,
and the provided TaqMan MicroRNA Assay mix containing pre-
formulated forward and reverse primers and the FAM-linked
TaqMan MGB probe. Assays were run in triplicate on an ABI
Prism 7000 SDS thermocycler as follows: 95uC for 10 min, and 40
cycles of 95uC for 15 s and 60uC for 1 min. All assays were
repeated at least twice. miRNA expression changes were
considered confirmed if the qPCR showed fold changes greater
than 2 in the correct direction and weak if the qPCR fold change
was less than 2, but in the correct direction.
Real-time qPCR, cloning and sequencing of predicted
miRNAs
Real-time qPCR assays for predicted miRNAs and positive
controls was performed using the NCodeTM GreenERTM miRNA
First-Strand cDNA Synthesis and qRT-PCR Kit (Invitrogen,
Burlington, Ontario, Canada) as described by the manufacturer,
using 1mg of total RNA. Assays were run on an ABI Prism 7000
SDS thermocycler as follows: 50uC for 2 min, 95uC for 10 min,
and 40 cycles of 95uC for 15 s and 57 or 60uC for 1 min. Primers
and annealing temperatures were as shown in Table 2. Ncode
PCR reactions were resolved by 4% agarose gel electrophoresis
and amplified products purified using the Geneclean Spin Kit (MP
Biomedicals, Solon, OH). The purified PCR amplicons were then
ligated into TOPO TA vectors (Invitrogen, Burlington, Ontario,
Canada) and subjected to DNA sequencing using the M13 reverse
primer at our in house facility.
Real-time qPCR of predicted miRNA host genes
Real-time qPCR assays for miRNA host gene mRNA was
carried out using the SuperScriptTMIII PlatinumH SYBRH Green
One-Step qRT-PCR Kit (Invitrogen, Burlington, Ontario,
Canada) as described by the manufacturer, using 1mg of total
RNA. Assays were run on an ABI Prism 7000 SDS thermocycler
as follows: 50uC for 3 min, 95uC for 5 min, and 40 cycles of 95uC
for 15 s and 60uC for 30 s. Primers were as shown in Table 2.
Target Prediction of predicted miRNAs
39-UTR regions of genes from the human genome (hg17) were
obtained using the UCSC genome browser (http://genome.ucsc.
edu/) [67]. The human REST 39-UTR sequence was obtained
from Packer et al., 2008 [19] and the mouse and dog sequences
were derived from the human sequence and obtained from the
UCSC genome browser using the Vertebrate Multiz Alignment &
Conservation track [67]. The miRNA binding site prediction
program miRanda [40] was installed locally and used to search for
miRNA target sites with the same parameters as used for miRNA
target prediction at microRNA.org (Score cutoff S.=140,
Energy cutoff E,=27.0, Gap opening: 29.0, Gap extension
24.0, 59 scaling: 4).
Supporting Information
Figure S1 Expression profiles of miRNAs. A. Summary table of
miRNAs expression and analysis. Complete expression profiles for
all miRNAs are presented in heatmap format. In addition, specific
comparisons were also performed. The figure indicates: (i)
miRNAs up- or down-regulated during the time course of RA
treatment based on the comparative analysis of NT2-undiff vs.
NT2-8D, NT2-8D vs. NT2-12D and NT2-undiff vs. NT2-28D
(labeled as Up and Down with respect to the earlier time-point); (ii)
miRNAs differentially expressed during terminal differentiation of
NT2 cells to neurons and astrocytes as reflected by the
comparisons of NT2-N vs. NT2-28D and NT2-A vs. NT2-28D
(labeled as Higher or Lower with respect to NT2-28D); (iii)
neuronal and astrocytic miRNAs (labeled as Neuronal or
Astrocytic) were designated based on their expression levels in
NT2-A vs. NT2-N and in primary human neurons vs. primary
astrocytes (PHN vs. PHAf and PHN vs. PHAe ). In all figures, the
intensity of the yellow scale in the heat map corresponds to the
mean log2 expression of miRNAs on the microarrays, from zero
and lower (black) to eight and higher (bright yellow). B. Expression
profiles of miRNAs differentially expressed in NT2 cells during the
RA time course. The figure shows miRNAs up- or down-regulated
during the RA time course based on the comparisons of NT2-
undiff vs. NT2-8D, NT2-8D vs. NT2-12D, and NT2-undiff vs.
NT2-28D (labeled as Up and Down with respect to the earlier
time-point). C. Expression profiles of miRNAs in terminally
differentiated NT2 cells. miRNAs differentially expressed during
the terminal differentiation of NT2 cells to neurons and astrocytes
as reflected by the comparisons of NT2N vs. NT2-28D and NT2A
vs. NT2-28D (labeled as Higher or Lower with respect to NT2-
28D). miRNAs were classified as neuronal or astrocytic based on
their expression levels in NT2-A vs. NT2-N. D. Expression profiles
of astrocytic and neuronal miRNAs. miRNAs classified as
neuronal or astrocytic based on their expression levels in NT2-A
vs. NT2-N as well as in primary human neurons and fetal or
embryonic astrocytes (PHN vs. PHAf and PHN vs. PHAe).
Found at: doi:10.1371/journal.pone.0011109.s001 (0.12 MB
XLS)
Figure S2 Expression patterns of miRNAs associated with the
central nervous system. The list of miRNAs and the information
regarding their reported functions in the CNS were taken from a
recent review of Zeng [51]. The figure shows their expression
patterns during RA-induced differentiation of NT2 cells (up- or
down- regulated in NT2-undiff vs. NT2-8D, NT2-undiff vs. NT2-
28D and NT2-8D vs. NT2-28D) and in NT2-N neurons and
NT2-A astrocytes (higher or lower in NT2N vs. NT2-28D and
NT2A vs. NT2-28D). miRNAs were classified as neuronal or
astrocytic based on their expression levels in terminally differen-
tiated NT2 cells (NT2-A vs. NT2-N) as well as in primary human
neurons and fetal astrocytes (PHN vs. PHAf ) or embryonic
astrocytes (PHN vs. PHAe).
Found at: doi:10.1371/journal.pone.0011109.s002 (0.03 MB
XLS)
Table S1 Real-time qPCR validation of microarray results.
Found at: doi:10.1371/journal.pone.0011109.s003 (0.03 MB
XLS)
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